Literature DB >> 10940792

Significance of the interleukin-1 receptor antagonist/interleukin-1 beta ratio as a prognostic factor in patients with pulmonary sarcoidosis.

T Mikuniya1, S Nagai, M Takeuchi, T Mio, Y Hoshino, H Miki, M Shigematsu, K Hamada, T Izumi.   

Abstract

BACKGROUND: Various factors such as serum angiotensin-converting enzyme (sACE) activity, bronchoalveolar lavage (BAL) fluid lymphocyte percent, CD4/CD8 ratio, and shadows on chest radiograph have been identified as indexes of disease activity in patients with sarcoidosis. However, it remains to be confirmed whether these factors can predict clinical outcomes.
OBJECTIVE: To examine whether the interleukin-1 receptor antagonist (IL-1ra)/IL-1 beta ratio can predict the clinical course, we prospectively followed the clinical courses of 30 patients with pulmonary sarcoidosis 4 years after measurement of immunoreactive amounts of IL-1ra or IL-1 beta in the culture supernatants obtained from BAL fluid macrophages.
METHODS: Immunoreactive amounts of IL-1ra or IL-1 beta were measured using ELISA. Changes in pulmonary function, sACE activity, and shadows on chest radiographs during observation periods were evaluated as markers of changes in disease activity.
RESULTS: We found that the patients whose shadows on chest radiographs showed improvement had a higher molar IL-1ra/IL-1 beta ratio than the patients whose shadows persistently remained 4 years after BAL examination (p < 0.05). The molar ratio was found to be positively correlated with improvement of percent vital capacity (p < 0.05) and negatively correlated with the ratio of sACE activity at the time of the last observation to sACE activity at the time of BAL (sACE(LAST)/sACE(BAL), p < 0.01). The sACE(LAST)/sACE(BAL) ratio was significantly lower in patients whose shadows on chest radiographs decreased than in those whose shadows remained unchanged (p < 0.005).
CONCLUSION: The IL-1ra/IL-1 beta ratio in the BAL fluid macrophage culture supernatants in patients with pulmonary sarcoidosis could be a useful marker in predicting the persistence of granulomatous lesions (chronicity). Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10940792     DOI: 10.1159/000029536

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  8 in total

1.  Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis.

Authors:  M Kolb; P J Margetts; D C Anthony; F Pitossi; J Gauldie
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 2.  Genetics of sarcoidosis: candidate genes and genome scans.

Authors:  Michael C Iannuzzi; Benjamin A Rybicki
Journal:  Proc Am Thorac Soc       Date:  2007-01

Review 3.  Cytokine modulators in the treatment of sarcoidosis.

Authors:  E Bargagli; C Olivieri; P Rottoli
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

4.  The Immunogenetics of Granulomatous Diseases.

Authors:  Gizem Filazi Kök; Ümit Türsen
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  HIF-1α regulates IL-1β and IL-17 in sarcoidosis.

Authors:  Jaya Talreja; Harvinder Talwar; Christian Bauerfeld; Lawrence I Grossman; Kezhong Zhang; Paul Tranchida; Lobelia Samavati
Journal:  Elife       Date:  2019-05-01       Impact factor: 8.140

Review 6.  Emerging Molecular Targets for the Treatment of Refractory Sarcoidosis.

Authors:  Gonçalo Boleto; Matheus Vieira; Anne Claire Desbois; David Saadoun; Patrice Cacoub
Journal:  Front Med (Lausanne)       Date:  2020-11-24

7.  Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: Anakinra Randomized Trial (MAGiC-ART).

Authors:  Jordana Kron; Thomas Crawford; Virginia Mihalick; Frank Bogun; Jennifer H Jordan; Todd Koelling; Huzaefah Syed; Aamer Syed; Thomas Iden; Kelly Polly; Emily Federmann; Kirsta Bray; Sangeeta Lathkar-Pradhan; Shilpa Jasti; Lynda Rosenfeld; David Birnie; Melissa Smallfield; Le Kang; Alpha Berry Fowler; Amy Ladd; Kenneth Ellenbogen; Benjamin Van Tassell; W Gregory Hundley; Antonio Abbate
Journal:  J Transl Med       Date:  2021-11-08       Impact factor: 5.531

8.  Pharmacological Inhibition of Chitotriosidase (CHIT1) as a Novel Therapeutic Approach for Sarcoidosis.

Authors:  Barbara Dymek; Piotr Sklepkiewicz; Michal Mlacki; Nazan Cemre Güner; Patrycja Nejman-Gryz; Katarzyna Drzewicka; Natalia Przysucha; Aleksandra Rymaszewska; Magdalena Paplinska-Goryca; Agnieszka Zagozdzon; Małgorzata Proboszcz; Łukasz Krzemiński; Jan H von der Thüsen; Katarzyna Górska; Karolina Dzwonek; Zbigniew Zasłona; Pawel Dobrzanski; Rafał Krenke
Journal:  J Inflamm Res       Date:  2022-09-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.